The EPS forecast of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for quarter closed 2017-03-31 is $-1.71.
Last week EPS prediction was $-1.71 and a month ago was $-1.71. EPS forecast preceding 2-months was $-1.71 while 90-days afore, it was $-1.71. EPS forecasts difference from last week is 0%.
EPS downgrade calls were 0 and upgrade recommendations last week were 0. Positive EPS review was 0, and 0 in the last month and 2-months, correspondingly. For last 90 and 120-days, it was 0 and 1.
EPS lowered in last 30 and 60-days was 0, and 0, correspondingly. Almost 90 and 120-days earlier, predicted EPS was 0 and 3, respectively. In preceding 18 days, the EPS revision on plus and minus side were 1 and 2 correspondingly.
For the period closed 3 mean EPS was $-1.71 calculated as per 12 predictions. It was quantified on 2016-11-07 and EPS was $-1.64. The surprise count was $-0.08 per share, or -5.13%. The standard deviation of posted EPS before financial report release is $0.06.
Quarterly Sales Estimates
The mean of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) yearly sales estimates is $2.09 while sales forecasts median is $2.09. The estimate is identified by 2 analysts for the fiscal 2017.
Highest yearly prediction is $2.2 and the lowest estimate is $1.98. Annual sales predictions asserted standard deviation of $0.155.
Number of professionals that revised equity price target positively last week was 2 while downgrade was 2. Mean estimate signified difference of 0%. Targets revised upside last month was 2 and downgrade was 2. From last monthly period, the predicted change is 0%.
Analysts rereading sales numbers on north side in the preceding quarter are 2 and almost 2
have upped marks. The difference of mean prediction is 0% from previous quarter.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...